Blocking the chaperone kinome pathway: Mechanistic insights into a novel dual inhibition approach for supra-additive suppression of malignant tumors

Biochemical and Biophysical Research Communications

Volumn 404, Issue 1, 2011, Pages 498-503

  Grover, Abhinav ^a   Shandilya, Ashutosh ^a   Agrawal, Vibhuti ^a   Pratik, Piyush ^a   Bhasme, Divya ^a   Bisaria, Virendra S ^a   Sundar, Durai ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY DELHI   (India)

Author keywords

17 DMAG; Chaperone; Hsp90; Withaferin A; Withania somnifera

Indexed keywords

ALVESPIMYCIN; CELL CYCLE PROTEIN 37; HEAT SHOCK PROTEIN 90; PROTEIN KINASE; WITHAFERIN A;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; DRUG BINDING; DRUG MECHANISM; DRUG TARGETING; INTROSPECTION; LIGAND BINDING; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DOCKING; MOLECULAR DYNAMICS; PRIORITY JOURNAL; THERMODYNAMICS;

ANTINEOPLASTIC AGENTS; BENZOQUINONES; CELL CYCLE PROTEINS; CHAPERONINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; LIGANDS; MOLECULAR CHAPERONES; MOLECULAR DYNAMICS SIMULATION; NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; THERMODYNAMICS; WITHANOLIDES;

WITHANIA SOMNIFERA;

EID: 78650852886     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.12.010     Document Type: Article

References (45)

1. Whitesell L., Lindquist S.L. HSP90 and the chaperoning of cancer. Nature Reviews Cancer 2005, 5:761-772.
2. Pearl L.H. Hsp90 and Cdc37-a chaperone cancer conspiracy. Current Opinion in Genetics & Development 2005, 15:55-61.
3. Calderwood S.K., Khaleque M.A., Sawyer D.B., Ciocca D.R. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends in Biochemical Sciences 2006, 31:164-172.
4. Ferrarini M., Heltai S., Zocchi M.R., Rugarli C. Unusual expression and localization of heat-shock proteins in human tumor-cells. International Journal of Cancer 1992, 51:613-619.
5. Welch W.J., Feramisco J.R. Purification of the major mammalian heat-shock proteins. Journal of Biological Chemistry 1982, 257:4949-4959.
6. Kamal A., Boehm M.F., Burrows F.J. Therapeutic and diagnostic implications of Hsp90 activation. Trends in Molecular Medicine 2004, 10:283-290.
7. Hunter T., Poon R.Y.C. Cdc37: a protein kinase chaperone?. Trends in Cell Biology 1997, 7:157-161.
8. Vaughan C.K., Gohlke U., Sobott F., Good V.M., Ali M.M.U., Prodromou C., Robinson C.V., Saibil H.R., Pearl L.H. Structure of an Hsp90-Cdc37-Cdk4 complex. Molecular Cell 2006, 23:697-707.
9. Silverstein A.M., Grammatikakis N., Cochran B.H., Chinkers M., Pratt W.B. P50(cdc37) binds directly to the catalytic domain of Raf as well as to a site on hsp90 that is topologically adjacent to the tetratricopeptide repeat binding site. Journal of Biological Chemistry 1998, 273:20090-20095.
10. Smith J.R., Clarke P.A., de Billy E., Workman P. Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors. Oncogene 2009, 28:157-169.
11. Gray P.J., Stevenson M.A., Calderwood S.K. Targeting Cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cells. Cancer Research 2007, 67:11942-11950.
12. Alhindawi M.K., Alkhafaji S.H., Abdulnabi M.H. Antigranuloma Activity of Iraqi Withania somnifera. Journal of Ethnopharmacology 1992, 37:113-116.
13. Mishra L., Singh B., Dagenias S. Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Alternative Medicine Review 2000, 5:334-336.
14. Mohan R., Hammers H., Bargagna-Mohan P., Zhan X., Herbstritt C., Ruiz A., Zhang L., Hanson A., Conner B., Rougas J., Pribluda V. Withaferin A is a potent inhibitor of angiogenesis. Angiogenesis 2004, 7:115-122.
15. Owais M., Sharad K.S., Shehbaz A., Saleemuddin M. Antibacterial efficacy of Withania somnifera (ashwagandha) an indigenous medicinal plant against experimental murine salmonellosis. Phytomedicine 2005, 12:229-235.
16. Kaileh M., Vanden Berghe W., Heyerick A., Horion J., Piette J., Libert C., De Keukeleire D., Essawi T., Haegeman G. Withaferin A strongly elicits I kappa B kinase beta hyperphosphorylation concomitant with potent inhibition of its kinase activity. Journal of Biological Chemistry 2007, 282:4253-4264.
17. Oh J.H., Kwon T.K. Withaferin A inhibits tumor necrosis factor-alpha-induced expression of cell adhesion molecules by inactivation of Akt and NF-kappa B in human pulmonary epithelial cells. International Immunopharmacology 2009, 9:614-619.
18. Ichikawa H., Takada Y., Shishodia S., Jayaprakasam B., Nair M.G., Aggarwal B.B. Withanolides potentiate apoptosis, inhibit invasion, and abolish osteoclastogenesis through suppression of nuclear factor-kappa B (NF-kappa B) activation and NF-kappa B-regulated gene expression. Molecular Cancer Therapeutics 2006, 5:1434-1445.
19. Samadi A.K., Mukerji R., Shah A., Bron T., Timmermann B.N., Cohen M.S. Withaferin-A is a novel HSF-1 inhibitor with potent antitumor effects in melanoma in vivo. Molecular Cancer Therapeutics 2009, 8.
20. Grover A., Shandilya A., Punetha A., Bisaria V.S., Sundar D. Inhibition of the NEMO/IKKβ association complex formation, a novel mechanism associated with the NF-κB activation suppression by Withania somnifera's key metabolite withaferin A. BMC Genomics 2010, 11:S25.
21. Grover A., Shandilya A., Bisaria V.S., Sundar D. Probing the anticancer mechanism of prospective herbal drug Withaferin A on mammals: a case study on human and bovine proteasomes. BMC Genomics 2010, 11:S15.
22. Whitesell L., Mimnaugh E.G., Decosta B., Myers C.E., Neckers L.M. Inhibition of heat-shock protein Hsp90-Pp60(V-Src) heteroprotein complex-formation by benzoquinone ansamycins-essential role for stress proteins in oncogenic transformation. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:8324-8328.
23. Sharma S.V., Agatsuma T., Nakano H. Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol. Oncogene 1998, 16:2639-2645.
24. Neckers L., Schulte T.W., Mimnaugh E. Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity. Investigational New Drugs 1999, 17:361-373.
25. Smith V., Sausville E.A., Camalier R.F., Fiebig H.H., Burger A.M. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemotherapy and Pharmacology 2005, 56:126-137.
26. Workman P., Burrows F., Neckers L., Rosen N. Drugging the cancer chaperone HSP90 combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Stress Responses in Biology and Medicine 2007, 1113:202-216.
27. Hollingshead M., Alley M., Burger A.M., Borgel S., Pacula-Cox C., Fiebig H.H., Sausville E.A. In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemotherapy and Pharmacology 2005, 56:115-125.
28. Ronnen E.A., Kondagunta G.V., Ishill N., Sweeney S.M., DeLuca J.K., Schwartz L., Bacik J., Motzer R.J. A phase II trial of 17-(allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Investigational New Drugs 2006, 24:543-546.
29. Sreeramulu S., Jonker H.R.A., Langer T., Richter C., Lancaster C.R.D., Schwalbe H. The human Cdc37.Hsp90 complex studied by heteronuclear NMR spectroscopy. Journal of Biological Chemistry 2009, 284:3885-3896.
30. NCBI-PubChem Compound database. Available from http://pubchem.ncbi.nlm.nih.gov/.
31. Cornell W.D., Cieplak P., Bayly C.I., Gould I.R., Merz K.M., Ferguson D.M., Spellmeyer D.C., Fox T., Caldwell J.W., Kollman P.A. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. Journal of the American Chemical Society 1996, 118:2309.
32. Stebbins C.E., Russo A.A., Schneider C., Rosen N., Hartl F.U., Pavletich N.P. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 1997, 89:239-250.
33. MacLean M., Picard D. Cdc37 goes beyond Hsp90 and kinases. Cell Stress & Chaperones 2003, 8:114-119.
34. Shao J.Y., Irwin A., Hartson S.D., Malts R.L. Functional dissection of Cdc37: characterization of domain structure and amino acid residues critical for protein kinase binding. Biochemistry 2003, 42:12577-12588.
35. Zhang W., Hirshberg M., McLaughlin S.H., Lazar G.A., Grossmann J.G., Nielsen P.R., Sobott F., Robinson C.V., Jackson S.E., Laue E.D. Biochemical and structural studies of the interaction of Cdc37 with Hsp90. Journal of Molecular Biology 2004, 340:891-907.
36. Terasawa K., Minami Y. A client-binding site of Cdc37. FEBS Journal 2005, 272:4684-4690.
37. Zhao Q., Boschelli F., Caplan A.J., Arndt K.T. Identification of a conserved sequence motif that promotes Cdc37 and cyclin D1 binding to Cdk4. Journal of Biological Chemistry 2004, 279:12560-12564.
38. Terasawa K., Yoshimatsu K., Iemura S., Natsume T., Tanaka K., Minami Y. Cdc37 interacts with the glycine-rich loop of Hsp90 client kinases. Molecular and Cellular Biology 2006, 26:3378-3389.
39. Roe S.M., Ali M.M.U., Meyer P., Vaughan C.K., Panaretou B., Piper P.W., Prodromou C., Pearl L.H. The mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37). Cell 2004, 116:87-98.
40. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., Olson A.J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. Journal of Computational Chemistry 1998, 19:1639-1662.
41. D.A. Case, T.A. Darden, T.E. Cheatham, C.L. Simmerling, J. Wang, R.E. Duke, R. Luo, R.C. Walker, W. Zhang, K.M. Merz, B. Roberts, B. Wang, S. Hayik, A. Roitberg, G. Seabra, I. Kolossváry, I.F. Wong, F. Paesani, J. Vanicek, X. Wu, S.R. Brozell, T. Steinbrecher, H. Gohlke, Q. Cai, X. Ye, J. Wang, M.J. Hsieh, G. Cui, D.R. Roe, D.H. Mathews, M.G. Seetin, C. Sagui, V. Babin, T. Luchko, S. Gusarov, A. Kovalenko, P.A. Kollman, AMBER 11, University of California, San Francisco, 2010.
42. Jorgensen W.L., Chandrasekhar J., Madura J.D., Impey R.W., Klein M.L. Comparison of simple potential functions for simulating liquid water. Journal of Chemical Physics 1983, 79:926-935.
43. Bayly C.I., Cieplak P., Cornell W.D., Kollman P.A. A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges-the Resp model. Journal of Physical Chemistry 1993, 97:10269-10280.
44. Cornell W.D., Cieplak P., Bayly C.I., Kollman P.A. Application of Resp charges to calculate conformational energies, hydrogen-bond energies, and free-energies of solvation. Journal of the American Chemical Society 1993, 115:9620-9631.
45. Berendsen H.J.C., Postma J.P.M., Vangunsteren W.F., Dinola A., Haak J.R. Molecular-dynamics with coupling to an external bath. Journal of Chemical Physics 1984, 81:3684-3690.